

# Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics

NCT07131007

---

Status	RECRUITING
Sponsor	Hebei Medical University Fourth Hospital
Enrollment	2,000 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- Patients with cancer who are receiving immune checkpoint inhibitor treatment.

### Exclusion (5)

- Active phase of severe autoimmune disease.
- Severe organ dysfunction.
- Presence of active infection.
- Pregnancy or lactation.
- Allergy to drug components.

## Locations (1 total)

---

Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China